CDW's (SGX:BXE) subsidiary, A Biotech's joint research with Neoregen for next-generation Lipid Nanoparticle (LNP) technology, reached the in vivo phase after positive results from the in vitro research phase, according to a filing with the Singapore Exchange on Tuesday.
The research is aimed at the development of mRNA vaccines and other treatments that can be used in cancer treatment and gene therapy.
The latest phase is expected to last around one year, and if successful, will allow CDW and Neoregen to license out the technology and enter into licensing negotiations with pharmaceutical companies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.